What is OnQuality Pharmaceuticals?
Based in Seattle, WA, OnQuality Pharmaceuticals is dedicated to pioneering drug development to solve multiple unmet clinical needs. The company focuses on improving both the quality-of-life and treatment outcomes for cancer patients, positioning itself as a key player in the oncology therapeutic space. Their commitment to innovation aims to address critical gaps in current cancer care.
How much funding has OnQuality Pharmaceuticals raised?
OnQuality Pharmaceuticals has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2021): $35M with participation from Shiyu Capital, BioTrack Capital, CASH Capital, and Matrix Partners China
Key Investors in OnQuality Pharmaceuticals
Shiyu Capital
Shiyu Capital is an investment firm focused on equity investment and asset allocation, particularly in the Chinese pharmaceutical industry, aiming to create value by combining industry resources with outstanding entrepreneurs.
BioTrack Capital
BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China, seeking innovative biotech and medtech companies led by outstanding entrepreneurs.
CASH Capital
CASH Capital is a leading investment management firm focused on hard technology sectors, managing significant assets and aiming to foster innovation by investing in high-tech enterprises, particularly in fields such as artificial intelligence and big data.
What's next for OnQuality Pharmaceuticals?
The recent major enterprise-level funding suggests OnQuality Pharmaceuticals is poised for significant scaling and advancement of its drug pipeline. This strategic investment will likely accelerate clinical trials, expand research and development capabilities, and potentially facilitate market entry for its lead candidates. The company's focus on unmet clinical needs in oncology indicates a strong potential for future growth and impact in the pharmaceutical sector.
See full OnQuality Pharmaceuticals company page
